Results are based on a study of low-dose interleukin-2 (IL-2) carried out at Dana-Farber Cancer Institute.
New real-world evidence shows low-dose interleukin-2 (LD IL-2) is safe and well tolerated at different dosing regimens in pediatric patients with steroid-refractory chronic graft-versus-host disease (GVHD).
Findings were published in Blood Advances, and they also reveal LD IL-2 is effective in combination with other immunosuppressive medications.
“With broadly immunosuppressive effects, corticosteroids remain the first-line therapy for chronic GVHD; however, prolonged steroid exposure is associated with significant morbidity, and 40% to 50% of patients are steroid refractory,” the authors wrote, underscoring the need for safe and effective therapies in this patient population.
The FDA has approved 3 second-line agents for refractory chronic GVHD: ibrutinib, ruxolitinib, and belumosudil. However, “an alternative approach to refractory chronic GVHD, developed at our center over the last 15 years, is to augment the Treg [regulatory T cells] compartment using LD IL-2. Interleukin-2 is an essential cytokine for the proliferation and function of both regulatory and effector T cells,” the researchers explained.
Five clinical trials carried out at Dana-Farber found subcutaneous LD IL-2 elicited partial responses in around 50% of adults and 82% of children by week 8.
The real-world evidence presented in the current paper includes data from 15 children and young adults. This paper also marks the first real-world evidence of LD IL-2 in pediatric patients for any disease indication. The retrospective chart review included individuals who received LD IL-2 from August 2016 to July 2022 and who were not enrolled in a research trial.
“While clinical trials are well-controlled settings that allow for standardized assessment and correlative studies, they are less permissive to practical aspects of therapy such as dose adjustments, changing concomitant therapies, and intermittent disruptions of therapy,” the researchers wrote.
The median patient age at the start of LD IL-2 was 10.4 (range, 1.2-23.2) years. Patients had a median time of 234 (range, 11-542) days from chronic GVHD diagnosis. In addition, patients had a median of 2.5 (range, 1-3) active organs at LD IL-2 start and received a median of 3 (range, 1-5) prior therapies.
Analyses revealed:
Responses for liver and skin chronic GVHD were particularly notable, data showed, as most patients achieved complete response in these organs.
“Low-dose interleukin-2 is a safe and well-tolerated therapy with promising efficacy for chronic GVHD and autoimmune disease,” the researchers said. “Our study reports the first off study clinical experience using LD IL-2. We also build on our center’s unique experience using LD IL-2 in pediatric patients with refractory chronic GVHD, including patients as young as 1.2 years of age.”
Despite the positive results, the authors note it is increasingly difficult to get insurance approval for LD IL-2 because new small molecules have been approved by the FDA for second-line therapy. More research is also needed with larger patient numbers to help determine baseline predictive factors for response to IL-2 and mechanisms of clinical improvement in different organs.
“Our study thus supports the use of LD IL-2 in steroid-refractory GVHD, which has a high clinical unmet need. In addition, these data make a compelling case for further exploring the use of LD IL-2 to promote immune tolerance in pediatric patients with autoimmune disease or following solid organ transplantation,” the researchers concluded.
Reference
Wobma H, Kapadia M, Kim HT, at al. Real-world experience with low dose- IL-2 for children and young adults with refractory chronic graft-versus-host disease. Blood Adv. Published online May 26, 2023. doi:10.1182/bloodadvances.2023009729
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Patients With MG Report Higher Azathioprine Discontinuation vs Other Immunosuppressants
May 15th 2024Survey data from over 200 patients showed that treatment discontinuation was lower for those taking mycophenolate or methotrexate than for those taking azathioprine for their myasthenia gravis (MG).
Read More
Bleeds and Resource Use in Hemophilia B: Retrospective Observational Study
May 15th 2024This real-world US study describes individuals with hemophilia B who experience bleeds despite factor replacement therapy and quantifies the associated comorbidity and health care resource utilization burden.
Read More
Valoctocogene Roxaparvovec Dramatically Reduces Bleeding in Hemophilia A
May 15th 2024New study findings demonstrate that valoctocogene roxaparvovec, a gene therapy for severe hemophilia A, significantly reduces bleeding episodes and dependency on factor VIII infusions over a 3-year period, while maintaining a favorable safety profile.
Read More